JPRN-UMIN000032854
Recruiting
未知
Immune checkpoint inhibitors and drug-induced colitis - Immune checkpoint inhibitors and drug-induced colitis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- patients who are going to administered immune checkpoint inhibitor
- Sponsor
- Shiga University of Medical Science
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients who can not obtain consent 2\. Patient undergoing antithrombotic therapy 3\. When polyps that were judged to be resected for adaptation at the time of the initial colonoscopy are discovered 4\. Patients with brachytherapy embedded for prostate cancer treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
Active, not recruiting
Phase 1
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-000058-24-NLErasmus MC Cancer Institute390
Recruiting
Phase 4
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.NSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656NL-OMON54425Erasmus MC, Universitair Medisch Centrum Rotterdam390
Recruiting
Not Applicable
Predictive biomarker study of immune checkpoint inhibitors in metastatic head and neck squamous cell carcinomaNeoplasmsKCT0007598ational Cancer Center50
Completed
Not Applicable
Incidence of immune checkpoint inhibitor-related myositisJPRN-UMIN000044960Yokohama City University Graduate School of Medicine12,866